TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03313856
Drug: Guazuma Ulmifolia plus Tecoma Stans
Normalized name: Guazuma ulmifolia leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
Study: NCT03255642
Drug: Melatonin 2mg
Normalized name: Vicks ZzzQuil PURE Zzzs Melatonin 2mg Extended-Release Tablet
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 weeks of 2mg prolonged release melatonin (Circadin)
Study: NCT01501435
Drug: CJ-30039
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT01304602
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
Study: NCT04522167
Drug: Eylea® (Aflibercept)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Study: NCT01368809
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Study: NCT00819884
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT02801565
Drug: Conventional controlled ovarian stimulation proctol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional controlled ovarian stimulation proctol without rhGH.
Study: NCT04279535
Drug: Topical Ascorbic Acid
Normalized name: ascorbic acid Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
Study: NCT01131845
Drug: UT-15C SR (treprostinil diethanolamine)
Normalized name: Diethanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, 1 mg UT-15C SR
Study: NCT02054299
Drug: Drug application Thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine: 200mg, single oral application
Study: NCT01833065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00507637
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
Study: NCT01834235
Drug: NPC-1C
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
Study: NCT01923649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for somatuline slow release 90 mg
Study: NCT00001212
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01224717
Drug: PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01224717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01564875
Drug: Simvast CR
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
Study: NCT00543725
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet once daily for 96 weeks
Study: NCT02630472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
Study: NCT00002984
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
Study: NCT03777085
Drug: TQB2303
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
Study: NCT01423292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00845845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo with dietary counseling for 24 weeks.
Study: NCT02169713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03242590
Drug: LPCN 1021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate
Study: NCT02398604
Drug: Allo-hMSCs
Normalized name: allo-2-hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic Human Mesenchymal Stem Cells
Study: NCT02398604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00412243
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Beginning dose 200 mg/m\^2 every 12 hours for 3 days
Study: NCT01674569
Drug: X-82 oral
Normalized name: Gas-X Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops
Study: NCT01026142
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 po twice daily for 14 days every 3 weeks
Study: NCT03316638
Drug: W0101 - Cohort A2
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered every 3 weeks
Study: NCT03316638
Drug: W0101 - Expansion Phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered according to the recommended dose for expansion
Study: NCT03014687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Study: NCT02228811
Drug: DCC-2701 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02824003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly dosing for 13 weeks
Study: NCT00567164
Drug: EE20/DRSP (BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
Study: NCT00567164
Drug: EE20/DRSP (YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
Study: NCT03383887
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before sleep
Study: NCT03383887
Drug: DAW1033D oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAW1033D before sleep
Study: NCT03736785
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02974010
Drug: Saline Solution Intravenous Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Study: NCT01594502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT02837380
Drug: VI/UMEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
Study: NCT02805244
Drug: JTZ-951, 14C-JTZ-951
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02952755
Drug: Co-administration of DWC20155/DWC20156
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02952755
Drug: DWC20162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01026142
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2 po twice daily for 14 days every 3 weeks
Study: NCT00413790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily
Study: NCT03681951
Drug: GSK3145095
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
Study: NCT00628251
Drug: AZD2281
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg Oral twice daily
Study: NCT00628251
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg/m2 Monthly Intravenous
Study: NCT00628251
Drug: AZD2281
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg oral twice daily
Study: NCT00002863
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01501214
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline given
Study: NCT00990678
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 400 mg calcium, 3 times daily
Study: NCT02073682
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
Study: NCT01638624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00089037
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004030
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01191957
Drug: Busulphan plus Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg
Study: NCT01965704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
Study: NCT04930952
Drug: Ethanol-amine Oleate Sclerotherapy Injection
Normalized name: Ethanolamine Oleate
DrugBank: Ethanolamine oleate (DB06689)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional Sclerotherapy Injection
Study: NCT00004360
Drug: chlorothiazide
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00081744
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01311895
Drug: 1+1
Normalized name: Prenazyme 1+1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?
Study: NCT00837213
Drug: Benzoyl peroxide with clindamycin
Normalized name: benzoyl peroxide / clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide wash - Clindamycin foam
Study: NCT00837213
Drug: Benzoyl peroxide with clindamycin and doxycycline
Normalized name: benzoyl peroxide / clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
Study: NCT02195375
Drug: Flutiform 500/20 µg BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02195375
Drug: Flutiform 250/10 µg BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02195375
Drug: Seretide Accuhaler 50/500 µg BID
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02648425
Drug: ASLAN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
Study: NCT02648425
Drug: cisplatin + capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
Study: NCT02648425
Drug: cisplatin + 5-fluorouracil (or+ Leucovorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks.
Study: NCT01723670
Drug: CHF 5074 2x
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 2x, once a day for 24 months
Study: NCT01723670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet,once a day for 24 months
Study: NCT02915263
Drug: IGIV-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
Study: NCT01069965
Drug: Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
Study: NCT01295593
Drug: valproic acid and 2-chlorodeoxyadenosine
Normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
Study: NCT04709094
Drug: Ethinyl Estradiol/Norethindrone
Normalized name: ETHINYL ESTRADIOL/NORETHINDRONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
Study: NCT02376972
Drug: PLACEBO VAGINAL TABLET
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
Study: NCT02376972
Drug: METROGEL VAGINAL
Normalized name: MetroGel Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
Study: NCT04370288
Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mixture of MCN will be injected to covid-19 patients.
Study: NCT01266525
Drug: SAR110894
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule~Route of administration: Oral
Study: NCT01266525
Drug: placebo (for SAR110894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule~Route of administration: Oral
Study: NCT03081884
Drug: FACBC PET-CT Imaging
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection.
Study: NCT00580801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
Study: NCT01463384
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg, twice daily for 6 months.
Study: NCT02128958
Drug: CF102
Normalized name: Cannabinoid Receptor Agonist CF102
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT02887313
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
Study: NCT02128958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12 hours
Study: NCT02565576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02565576
Drug: CFZ533
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00666406
Drug: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 50 +/- 5 IU/kg bodyweight
Study: NCT00590603
Drug: Arsenic Trioxide, Ascorbic Acid and Bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I.
Study: NCT04528719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT00902512
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viagra® 100 mg tablet, administered with water single dose
Study: NCT00921830
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
Study: NCT00542386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
Study: NCT00614406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet daily.
Study: NCT00820118
Drug: Structured treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day
Study: NCT03784677
Drug: TRPV6 Calcium Channel Inhibitor SOR-C13
Normalized name: SOR-C13
DrugBank: SOR-C13 (DB15366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03643627
Drug: SYNT001
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV infusion
Study: NCT03643627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV infusion
Study: NCT04511650
Drug: Placebo Subcutaneous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
Study: NCT01044056
Drug: norelgestrominum and ethinylestradiol patch oral contraceptive patch
Normalized name: norelgestromin and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
Study: NCT00859573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive substance
Study: NCT00902512
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg CT administered with water single dose
Study: NCT02392676
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study: NCT00946751
Drug: Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01565928
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 40 mg capsules, orally, once per day
Study: NCT03009734
Drug: ATx201 dermal formulations 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ATx201 dermal formulations 2%
Study: NCT03914651
Drug: 300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
Study: NCT03914651
Drug: 150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.